

# Bruno Detournay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1361971/publications.pdf>

Version: 2024-02-01

45  
papers

823  
citations

516710

16  
h-index

526287

27  
g-index

59  
all docs

59  
docs citations

59  
times ranked

837  
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity morbidity and health care costs in France: an analysis of the 1991-1992 Medical Care Household Survey. <i>International Journal of Obesity</i> , 2000, 24, 151-155.	3.4	64
2	Managing type 2 diabetes in France: the ECODIA survey. <i>Diabetes and Metabolism</i> , 2000, 26, 363-9.	2.9	61
3	Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. <i>Diabetes Care</i> , 2021, 44, 1368-1376.	8.6	59
4	The SCOPE Study: Health-Care Consumption Related to Patients with Chronic Obstructive Pulmonary Disease in France. <i>Value in Health</i> , 2004, 7, 168-174.	0.3	55
5	Prevalence of diagnosed type 2 diabetes mellitus in the French general population: The INSTANT study. <i>Diabetes and Metabolism</i> , 2009, 35, 25-31.	2.9	49
6	Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2. <i>Medecine Des Maladies Metaboliques</i> , 2017, 11, 577-593.	0.1	48
7	Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. <i>Diabetes and Metabolism</i> , 2012, 38, 102-112.	2.9	33
8	Prevalence of macrovascular complications and cardiovascular risk factors in people treated for diabetes and living in France: The ENTRED study 2001. <i>Diabetes and Metabolism</i> , 2008, 34, 140-147.	2.9	28
9	Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. <i>Diabetes Therapy</i> , 2016, 7, 537-549.	2.5	28
10	Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis. <i>PharmacoEconomics - Open</i> , 2018, 2, 209-219.	1.8	28
11	Economic Evaluation of Enoxaparin Sodium versus Heparin in Unstable Angina. <i>Pharmacoeconomics</i> , 2000, 18, 83-89.	3.3	27
12	A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. <i>International Journal of Public Health</i> , 2011, 56, 153-162.	2.3	24
13	Insulin therapy for diabetes mellitus: Treatment regimens and associated costs. <i>Diabetes and Metabolism</i> , 2012, 38, 156-163.	2.9	23
14	An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102521.	2.0	20
15	DIABEO System Combining a Mobile App Software With and Without Telemonitoring Versus Standard Care: A Randomized Controlled Trial in Diabetes Patients Poorly Controlled with a Basal-Bolus Insulin Regimen. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 904-911.	4.4	18
16	Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. <i>Vascular Health and Risk Management</i> , 2015, 11, 417.	2.3	15
17	Remote Monitoring of Diabetes: A Cloud-Connected Digital System for Individuals With Diabetes and Their Health Care Providers. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 1161-1168.	2.2	15
18	Flu vaccine coverage for recommended populations in France. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 670-675.	5.0	15

#	ARTICLE	IF	CITATIONS
19	Therapeutic management of orally treated type 2 diabetic patients, by French general practitioners in 2010: the DIAttitude Study. <i>Diabetes and Metabolism</i> , 2012, 38, S36-S46.	2.9	14
20	DIABEO App Software and Telemedicine Versus Usual Follow-Up in the Treatment of Diabetic Patients: Protocol for the TELESAGE Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e66.	1.0	13
21	Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 611-618.	4.4	13
22	Epidemiology and costs of diabetes treated with insulin in France. <i>Diabetes and Metabolism</i> , 2005, 31, 3-18.	2.9	12
23	Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101396.	2.0	10
24	Prise de position de la Société Francophone du Diabète (SFD) : Évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2. <i>Medicine Des Maladies Metaboliques</i> , 2019, 13, 195-209.	0.1	7
25	Costs and management of patients with hemophilia A in France: the Hemraude study. <i>European Journal of Health Economics</i> , 2022, 23, 23-32.	2.8	7
26	Cost of Inpatient Management of Hypoglycaemia in France. <i>Value in Health</i> , 2013, 16, A436.	0.3	6
27	Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database. <i>Diabetes Therapy</i> , 2020, 11, 535-548.	2.5	6
28	Le coût de l'insulinothérapie chez les patients diabétiques de type 2, en France. <i>Medicine Des Maladies Metaboliques</i> , 2015, 9, 3S30-3S33.	0.1	5
29	Coût des hospitalisations pour hypoglycémie en France chez les patients diabétiques de type 2 : Étude fondée sur le PMSI et la base EGB de la CNAMTS. <i>Medicine Des Maladies Metaboliques</i> , 2017, 11, IIS16-IIS19.	0.1	5
30	Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. <i>International Journal of COPD</i> , 2019, Volume 14, 447-456.	2.3	5
31	Pratique de l'auto-surveillance glycémique en France : données d'une enquête nationale. <i>Sante Publique</i> , 2017, Vol. 29, 229-240.	0.1	5
32	Prévalence et coût du diabète en France : où en est-on?. <i>Medicine Des Maladies Metaboliques</i> , 2007, 1, 95-98.	0.1	4
33	Aspects épidémiologiques et économiques de l'insulinothérapie en France métropolitaine. <i>Medicine Des Maladies Metaboliques</i> , 2008, 2, S149-S152.	0.1	4
34	Coût des traitements du diabète en France. <i>Medicine Des Maladies Metaboliques</i> , 2017, 11, IIS20-IIS23.	0.1	4
35	Déterminants des coûts du passage à l'insuline en France chez le patient diabétique de type 2 : quelles pistes d'optimisation?. <i>Sante Publique</i> , 2016, Vol. 28, 781-789.	0.1	4
36	Coût direct des AVK en France. <i>Archives of Cardiovascular Diseases Supplements</i> , 2016, 8, 174-179.	0.0	3

#	ARTICLE	IF	CITATIONS
37	Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 1861-1872.	2.5	3
38	Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France. <i>PharmacoEconomics - Open</i> , 2021, 5, 211-219.	1.8	2
39	Public health impact of human papillomavirus vaccination on prevention of cervical cancer in France. <i>International Journal of Public Health</i> , 2012, 57, 149-158.	2.3	1
40	Pratique de lâ€™autosurveillance glycÃ©mique en France : donnÃ©es dâ€™une enquÃªte nationale. <i>Medecine Des Maladies Metaboliques</i> , 2017, 11, 458-467.	0.1	1
41	Clinical added value of drugs: An empirical survey of French transparency committee opinions. <i>Therapie</i> , 2018, 76, 639-645.	1.0	1
42	France's competitiveness in global pharmaceutical research: The situation is improving. <i>Therapie</i> , 2021, 76, 549-557.	1.0	0
43	Le coÃ»t de lâ€™obÃ©sitiÃ© en France. <i>Medecine Des Maladies Metaboliques</i> , 2021, 15, 413-417.	0.1	0
44	ConsÃ©quences Ã©conomiques du non-respect des rÃ©gles dâ€™arrÃªt des agonistes des rÃ©cepteurs du GLP-1 au moment du passage Ã lâ€™insuline en France. <i>Medecine Des Maladies Metaboliques</i> , 2021, 15, 537-541.	0.1	0
45	Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: the SFDT1 study. <i>Diabetes and Metabolism</i> , 2021, 48, 101306.	2.9	0